Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 2
2001 1
2002 5
2003 1
2004 5
2005 4
2006 6
2007 4
2008 3
2009 9
2010 2
2011 4
2012 8
2013 12
2014 11
2015 9
2016 8
2017 7
2018 5
2019 7
2020 3
2021 16
2022 10
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24737786

125 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, Geborek P, Neovius M. Eriksson JK, et al. Ann Rheum Dis. 2015 Jun;74(6):1094-101. doi: 10.1136/annrheumdis-2013-205060. Epub 2014 Apr 15. Ann Rheum Dis. 2015. PMID: 24737786 Free PMC article. Clinical Trial.
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P. Karlsson JA, et al. Ann Rheum Dis. 2013 Dec;72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29. Ann Rheum Dis. 2013. PMID: 23196701 Clinical Trial.
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M, Bratt J. van Vollenhoven RF, et al. Lancet. 2009 Aug 8;374(9688):459-66. doi: 10.1016/S0140-6736(09)60944-2. Lancet. 2009. PMID: 19665644 Clinical Trial.
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group. van Vollenhoven RF, et al. Lancet. 2012 May 5;379(9827):1712-20. doi: 10.1016/S0140-6736(12)60027-0. Epub 2012 Mar 29. Lancet. 2012. PMID: 22464340 Clinical Trial.
125 results